The new vaccine approach will help improve survival rates for ‘the next decades and more’, says Cancer Research UK’s chief clinician
The world’s first personalised mRNA cancer vaccine for melanoma halves the risk of patients dying or the disease returning, according to trial results that doctors described as “extremely impressive”.
Melanoma affects more than 150,000 people a year globally, according to 2020 figures from World Cancer Research Fund International.
Continue reading… The Guardian Read More The new vaccine approach will help improve survival rates for ‘the next decades and more’, says Cancer Research UK’s chief clinicianThe world’s first personalised mRNA cancer vaccine for melanoma halves the risk of patients dying or the disease returning, according to trial results that doctors described as “extremely impressive”.Melanoma affects more than 150,000 people a year globally, according to 2020 figures from World Cancer Research Fund International. Continue reading…
